Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.92 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL28519848 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL5144255 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL466 | 1.00 | SLC22A1 (0.92) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL9416676 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL2123749 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL25325582 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL2705733 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL4056559 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL6622741 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 | |
| Tetrabuthylammonium SCHEMBL5484505 | 0.96 | SLC22A1 (0.86) | SLC22A1SLC22A2TSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0413289-B1 | Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC (US) | 1995-02-01 | — | — | EP | claimed |
| EP-0413289-A2 | Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1991-02-20 | — | — | EP | claimed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-110462402-B | Substance for preventing inhibition of antigen-antibody reaction by body fluid | 日本火腿株式会社 | 2024-06-25 | — | — | CN | disclosed |
| CN-115003655-A | Cycloalkyl urea derivatives | 住友制药株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114099368-A | Dental polishing paste | 义获嘉伟瓦登特公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-112912371-A | Flavone derivatives for treating and preventing hepatitis B virus diseases | 豪夫迈·罗氏有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-106795117-B | Heterobicyclic compounds and their use for the treatment of tuberculosis | 大塚制药株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| EP-1124565-B1 | AZIDO DERIVATIVES OF BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NAT RECH SCIENT (FR) | 2006-03-29 | — | — | EP | disclosed |
| EP-1124839-B1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NAT RECH SCIENT (FR) | 2006-01-11 | — | — | EP | disclosed |
| US-5346921-A | Treatment of inflammation with 15-keto-prostaglandin compounds | R-TECH UENO, LTD. (JP) | 1994-09-13 | — | — | US | disclosed |
| US-5252605-A | Promotion of wound-healing with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1993-10-12 | — | — | US | disclosed |
| US-5212324-A | TREATMENT OF CATARACT WITH 15-KETO-PROSTAGLANDIN COMPOUNDS | R.-TECH UENO LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| EP-0503887-A2 | Promotion of wound-healing with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
| US-5110821-A | Picornavirus | STERLING DRUG INC. (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0467564-A2 | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1992-01-22 | — | — | EP | disclosed |
| EP-0453127-A2 | Treatment of cataract with 15-keto-prostaglandin compounds | R-TECH UENO LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0413289-A2 | Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents | STERLING WINTHROP INC. (US) | 1991-02-20 | — | — | EP | disclosed |
| US-4945164-A | 1,3,4-Oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents and intermediates thereof | STERLING DRUG INC. (US) | 1990-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004166-A1 | ARYLOXYALKYLENE-SUBSTITUTED HYDROXYPHENYLHEXYNOIC ACIDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | HCAR1, HCAR3, CYP2C9 | SLC22A1 779/4885SLC22A2 1133/4885TSHR 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.